|
2025 Conference Publication Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304)Horvath, Lisa, Lin, Hui-Ming, Davis, Ian D., Martin, Andrew James, Yeung, Nicole, Kim, Rachel MN, Portman, Neil, Joshua, Anthony M., McJannett, Margaret Mary, Subhash, Vinod, Yip, Sonia, North, Scott A., McDermott, Raymond S., Chi, Kim N., Stockler, Martin R., Sweeney, Christopher and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304). 2025 ASCO Annual Meeting, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5093 |
|
2025 Conference Publication Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901)Emmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M., Nguyen, Andrew, Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Hofman, Michael S., Sandhu, Shahneen, Martin, Andrew James, Thomas, Hayley, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ 177 Lu] Lu-PSMA-617 (ANZUP1901). 2025 ASCO Annual Meeting, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5011 |
|
2025 Conference Publication Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)Munzur, Aslı Doğa, Herberts, Cameron, Kwan, Edmond Michael, Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Zhang, Alison Yan, Williams, Scott G., Bacon, Jack V.W., Azad, Arun, Davis, Ian D., Hofman, Michael S., Wyatt, Alexander William and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603). 2025 ASCO Annual Meeting I, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5020 |
|
2025 Conference Publication 177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)Sandhu, Shahneen, Subramaniam, Shalini, Thomas, Hayley, Tan, Thean Hsiang, Goh, Jeffrey C., Dhiantravan, Nattakorn, Weickhardt, Andrew James, Joshua, Anthony M., Kirkwood, Ian David, Lee, Sze Ting, Gedye, Craig, Nguyen, Andrew, Pattison, David A., Alipour, Ramin, Francis, Roslyn J., Hofman, Michael S., Martin, Andrew James, Stockler, Martin R., Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). 177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001). 2025 ASCO Annual Meeting I, Chicago, IL, United States, 30 May - 3 June 2025. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.5016 |
|
2025 Conference Publication Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Sandhu, Shahneen, Zhang, Alison Yan, Hofman, Michael S., Thomas, Hayley, Martin, Andrew James, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Overall survival and quality of life with [ 177 Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.17 |
|
2024 Conference Publication EV430/#358 Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysisObermair, Andreas, West, Zoe, Baxter, Eva, Condous, George, Hacker, Neville, Lord, Sally, Mccarthy, Sandie, Janda, Monika, Tuffaha, Haitham, Hayes, Sandi, Disipio, Tracey, Mellon, Anne, Gebski, Val, Mcnally, Orla and Martin, Andrew (2024). EV430/#358 Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis. IGCS 2024 Annual Meeting, Dublin, Ireland, 16-18 October 2024. London, United Kingdom: BMJ Group. doi: 10.1136/ijgc-2024-igcs.551 |
|
2024 Conference Publication Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)Hamid, A.A., Thomas, H., Martin, A., Soon, Y.Y., Horvath, L.G., Zielinski, R., Thomson, A., Tan, H., Sandhu, S.K., Reaume, M.N., Pook, D.W., Parnis, F., McDermott, R.S., Lawrence, N., Frydenberg, M., Chi, K.N., Stockler, M.R., Davis, I.D. and Sweeney, C. (2024). Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.1699 |
|
2024 Conference Publication Dynamic change in tumour PSMA expression between baseline and day 15 after commencing enzalutamide in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901)Emmett, L., Swiha, M., Papa, N., Subramaniam, S., Crumbaker, M., Joshua, A., Nguyen, A., Weickhardt, A., Lee, S., Ng, S., Francis, R. J., Goh, J. C., Pattison, D. A., Sandhu, S., Pathmanandavel, S., Kumar, A. S. Ravi, Hofman, M. S., Gedye, C., Rutherford, N., Thomas, H., Martin, A. J., Stockler, M. S. and Davis, I. D. (2024). Dynamic change in tumour PSMA expression between baseline and day 15 after commencing enzalutamide in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901). Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 19 - 23 October 2024. Heidelberg, Germany: Springer. |
|
2024 Conference Publication Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)Horvath, L.G., Lin, H-M., Davis, I.D., Martin, A., Scheinberg, T., Meikle, P., Joshua, A., Mcjannett, M., Subhash, V., Yip, S., North, S., McDermott, R.S., Chi, K.N., Stockler, M.R. and Sweeney, C. (2024). Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.1688 |
|
2024 Conference Publication Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [<sup>177</sup>Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Kwan, Edmond Michael, Hofman, Michael S., Ng, Sarah W. S., Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Donnellan, Gráinne, Annala, Matti, Tolmeijer, Sofie H., Azad, Arun, Davis, Ian D., Wyatt, Alexander William and TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May-4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.5055 |
|
2024 Conference Publication Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Kwan, Edmond Michael, Hofman, Michael S., Ng, Sarah W. S., Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Tolmeijer, Sofie H., Azad, Arun, Davis, Ian D. and Wyatt, Alexander William (2024). Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). Special Clinical Science Symposia, Chicago, IL, United States, 29 May - 4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.5055 |
|
2023 Conference Publication Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)Gedye, C., Harris, C. A., Stockler, M. R., Morris, M., Ferguson, T., Goh, J. C. H., Martin, A., Underhill, C. R., Pook, D., Krieger, L. E. M., Kichenadasse, G., Joshi, A. J., Subramaniam, S., Zebic, D. S., Zhang, A., Joshua, A. M., Toner, G. C., Vasey, P. A., Prithviraj, P. and Davis, I. D. (2023). Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.1116 |
|
2023 Conference Publication Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)Horvath, L. G., Davis, I. D., Martin, A., Zielinski, R., Thomson, A., Tan, T. H., Sandhu, S. K., Reaume, M. N., Pook, D., Parnis, F., North, S., Marx, G. M., McCaffrey, J. A., McDermott, R. S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K. N. N., Stockler, M. R. and Sweeney, C. (2023). Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.2742 |
|
2023 Conference Publication Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Weickhardt, A. J., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C. H., Pattison, D. A., Tan, H., Kirkwood, I. D., Sandhu, S. K., Nguyen, A., Gedye, C., Rutherford, N., Hofman, M., Martin, A., Stockler, M. R. and Davis, I. D. (2023). Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.10.086 |
|
2023 Conference Publication Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.16_suppl.TPS4617 |
|
2023 Conference Publication SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivorsJefford, Michael, Emery, Jon D., Martin, Andrew James, Lourenco, Richard De Abreu, Lisy, Karolina, Mohamed, Mustafa Abdi, King, Dorothy, Tebbutt, Niall C., Lee, Margaret, Mehrnejad, Ashkan, Burgess, Adele, Marker, Julie, Eggins, Renee, Carrello, Joseph, Thomas, Hayley and Schofield, Penelope (2023). SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2023. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102 |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication Effects of [<SUP>177</SUP>Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysisSoon, Yu Yang, Marschner, Ian, Hofman, Michael S., Emmett, Louise, Davis, Ian D., Stockler, Martin R. and Martin, Andrew James (2023). Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2023. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2023 Conference Publication Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271 |
